STOCK TITAN

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.

The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com
617.599.8178


FAQ

When will Apellis Pharmaceuticals, Inc. present at the 42nd Annual J.P. Morgan Healthcare Conference?

Apellis Pharmaceuticals, Inc. will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 9:45 a.m. PT.

Where can I watch the live webcast of Apellis Pharmaceuticals, Inc.'s presentation?

The live webcast of Apellis Pharmaceuticals, Inc.'s presentation will be available on the 'Events and Presentations' page of the 'Investors and Media' section of the company’s website.

Will there be a replay of Apellis Pharmaceuticals, Inc.'s webcast?

Yes, a replay of Apellis Pharmaceuticals, Inc.'s webcast will be available for approximately 30 days following the event.

Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Stock Data

5.76B
81.04M
13.24%
95.98%
8.66%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About APLS

apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.